Evidence map›Paper›PMID 34123415›Full record

ArticleJournal of ophthalmology2021

Challenges in Patients with Trisomy 21: A Review of Current Knowledge and Recommendations.

Jennifer Robinson, Manca Tekavčič Pompe, Christina Gerth-Kahlert

Open access · goldAbstract read
In one paragraph

Article in Journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Jennifer RobinsonDepartment of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-4533-9628
Manca Tekavčič PompeUniversity Eye Clinic, Ljubljana, Slovenia.ORCID https://orcid.org/0000-0003-3730-0229
Christina Gerth-KahlertDepartment of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-6298-615X
University of Zurich · CHLjubljana University Medical Centre · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo summarize and review the common ophthalmic anomalies in children with trisomy 21 (Down syndrome) in order to propose an update to current clinical recommendations.

methodsA retrospective chart review, systemic literature review, and international survey of the frequency of ocular abnormalities, screening schedules, and challenging aspects examining children with trisomy 21. The chart review included patients treated at the Department of Ophthalmology at the University Hospital of Zurich over a two-year period. The international survey was submitted to the members of the Swiss Society of Ophthalmology, Slovenian Ophthalmological Society, and European Pediatric Ophthalmology Society.

resultsAnalysis of 52 patient records during the study period revealed refractive errors (astigmatism: 54% of patients, hyperopia: 26%, and myopia: 15%) as the most common diagnosis, whereas childhood cataract was reported in 5%. This is in concordance with the extended literature review of 249 publications, although congenital cataracts were reported to be higher than at our institution. The survey participants reported great challenges in taking care of these patients, despite their long professional experience (73% with over 10 years of experience).

conclusionCare and treatment of children with trisomy 21 continues to be demanding for paediatric ophthalmologists. We recommend the following examination schedule for these patients: first, ophthalmological examination at 6-12 months of age, then once in 3-6 months for children under 2 years of age, once in 6 months for children 2-5 years of age, annually for children 5-10 years of age, and thereafter, to be decided on an individual basis depending on the presenting ocular abnormalities of the patient.

Identifiers

PMID34123415
PMCPMC8172292
OpenAlexW3164498976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.